Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

Jing Nie,Chunmeng Wang,Yang Liu,Qingming Yang,Qian Mei,Liang Dong,Xiang Li,Jiejie Liu,Wenjing Ku,Yan Zhang,Meixia Chen,Xiaojing An,Lu Shi,Malcolm V. Brock,Jie Bai,Weidong Han

Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.

2019

Jing Nie
Chunmeng Wang
Yang Liu
Qingming Yang
Qian Mei
Liang Dong
Xiang Li
Jiejie Liu
Wenjing Ku
Yan Zhang
Meixia Chen
Xiaojing An
Lu Shi
Malcolm V. Brock
Jie Bai
Weidong Han

PURPOSEAnti–programmed death-1 (PD-1) monotherapy induces a high response rate in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but complete remission (CR) is infrequently obser...

Keywords:

Lymphoma
Antibody
Refractory
Decitabine
Pathology
Oncology
Classical Hodgkin lymphoma
Medicine
Internal medicine
in patient
low dose
relapsed refractory
anti pd 1
complete remission

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations